Advertisement

 

 

Resveratrol effect on NAFLD patients: it is a matter of dose and treatment length.

Resveratrol effect on NAFLD patients: it is a matter of dose and treatment length.
Author Information (click to view)

Fogacci F, Banach M, Cicero AFG,


Fogacci F, Banach M, Cicero AFG, (click to view)

Fogacci F, Banach M, Cicero AFG,

Advertisement

Diabetes, obesity & metabolism 2018 04 15() doi 10.1111/dom.13324
Abstract

We have read with great interest and a little criticism the study of Kantartizis and collaborators recently published in Diabetes Obesity and Metabolism.[1] Our concerns regard the fact that, after investigating the 3-month effect of resveratrol 150 mg daily on 112 overweight or obese insulin resistant patients with non-alcoholic fatty liver disease [NAFLD], authors conclude that resveratrol supplementation does not affect liver fat content nor cardio-metabolic parameters in humans. This observation could be particularly negative since it is well-known that the cardiovascular disease risk of NAFLD patients is significantly increased when compared with non NAFLD subjects.[2].

Submit a Comment

Your email address will not be published. Required fields are marked *

8 − 1 =

[ HIDE/SHOW ]